1. Signaling Pathways
  2. GPCR/G Protein
    Neuronal Signaling
  3. Dopamine Receptor
  4. Dopamine Receptor Agonist

Dopamine Receptor Agonist

Dopamine Receptor Agonists (226):

Cat. No. Product Name Effect Purity
  • HY-169136
    U 101958
    Agonist
    U 101958 is full Dopamine D4 receptor agonist, with a pEC50 of 8.7 in HEK293/D4 cells .
  • HY-144291
    LY3154885
    Agonist
    LY3154885 is an orally active dopamine D1 receptor positive allosteric modulator (PAM). LY3154885 has an improved agent-agent interactions (DDI) risk profile.
  • HY-141496
    A-77636
    Agonist
    A-77636 is an orally active, potent, selective and long-acting dopamine D1 receptor agonist (pEC50 = 8.13; EC50 = 1.1 nM). A-77636 shows the highest affinity (pKi = 7.40 ± 0.09; Ki = 39.8 nM) for the dopamine D1 receptor. A-77636 shows antiparkinsonian activity.
  • HY-116445
    UNC9975
    Agonist
    UNC9975 is a D2R agonist that displays signaling bias via β-arrestin–ergic signaling and a simultaneously antagonist of Gi-regulated cAMP production and partial agonist for D2R/β-arrestin-2 interactions. UNC9975 can be utilized in antipsychotic research.
  • HY-15296S1
    Cabergoline-d6
    Agonist
    Cabergoline-d6 is deuterium labeled Cabergoline. Cabergoline is an ergot derived-dopamine D2-like receptor agonist that has high affinity for D2, D3, and 5-HT2B receptors (Ki=0.7, 1.5, and 1.2, respectively).
  • HY-106889
    Zelandopam free base
    Agonist
    Zelandopam free base (YM435 free base) is an orally active and selective agonist of the dopamine D1 receptor. Zelandopam free base possesses potent renal vasodilatory properties and can effectively alleviate Cisplatin (HY-17394)-induced acute renal failure.
  • HY-15394S
    (Rac)-Rotigotine-d7 hydrochloride
    Agonist
    (Rac)-Rotigotine-d7 (hydrochloride) is deuterium labeled (Rac)-Rotigotine (hydrochloride). (Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with Kis of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.
  • HY-134015
    7-Hydroxy-DPAT
    Agonist
    7-Hydroxy-DPAT (7-OH-DPAT) is a selective D3 dopamine receptor agonist. 7-Hydroxy-DPAT exhibits significant pharmacological activity in modulating locomotor behavior and dopamine metabolism within the brain. 7-Hydroxy-DPAT can be used for the research of neurological disease .
  • HY-116820
    OS-3-106
    Agonist
    OS-3-106 is a potent, BBB-penetrated and selective dopamine D3 receptor (D3R) agonist. OS-3-106 binds with high affinity (Ki = 0.2 nM) at the D3R. OS-3-106 can be used for psychoactivator addiction research.
  • HY-103411
    SKF83822 hydrobromide
    Agonist
    SKF83822 hydrobromide is a potent dopamine D1 receptor agonist. SKF83822 hydrobromide activates Gs/olf/adenylyl cyclase (AC)-coupled D1 receptors, but not phospholipase C (PLC)-coupled D1-like receptors.
  • HY-155099
    FGH31
    Agonist
    FGH31 (Compound 24) is a potent, selective, GRK2 dependency dopamine D4 agonist, with the Ki of 1.6 nM. FGH31 partial activates β- arrestin.
  • HY-121775
    PF-00217830
    Agonist
    F-00217830 is an agonist ofDopamine D2 receptor. PF-00217830 inhibits of spontaneous locomotor activity and 2,5-dimethoxy-4-iodoamphetamine-induced head twitches in rats.
  • HY-P3958
    BIM-23027
    Agonist 99.76%
    BIM-23027 is a selective agonist of sst2 receptor (EC50=0.32 nM), with similar effect to somatostatin (SRIF), a cyclic tetradecapeptide. BIM-23027 stimulates dopamine release, which is mediated by a Glu-dependent mechanism.
  • HY-106889A
    Zelandopam anhydrous
    Agonist
    Zelandopam (anhydrous) (YM435 (anhydrous)) is an orally active and selective agonist of the dopamine D1 receptor. Zelandopam (anhydrous) possesses potent renal vasodilatory properties and can effectively alleviate Cisplatin (HY-17394)-induced acute renal failure.
  • HY-122495
    rel-Quinpirole dihydrochloride
    Agonist
    rel-Quinpirole (rel-LY 171555) dihydrochloride, an ergot compound, is a selective dopamine (DA) D2 receptor agonist. rel-Quinpirole dihydrochloride can be used for research on neurological diseases.
  • HY-107002
    Lergotrile
    Agonist
    Lergotrile is a potent and orally active dopamine agonist and a prolactin secretion inhibitor. Lergotrile inhibits prolactin release from pituitaries by activating an adenohypophyseal dopamine receptor. Lergotrile has the potential for the research of Parkinson's disease.
  • HY-10349AR
    WAY-100635 maleate (Standard)
    Agonist
    WAY-100635 (maleate) (Standard) is the analytical standard of WAY-100635 (maleate). This product is intended for research and analytical applications. WAY-100635 maleate is a potent and selective 5-hydroxytryptamine 1A (5-HT1A) receptor antagonist with an IC50 value of 0.91 nM and Ki value of 0.39 nM. WAY-100635 maleate has pIC50 values for 5-HT1A and α1-adrenergic receptors of 8.9 and 6.6, respectively. WAY-100635 maleate is also a potent dopamine D4 receptor agonist.
  • HY-115192
    ent-Naxagolide hydrochloride
    Agonist
    ent-Naxagolide (ent-MK-458) hydrochloride is a dopamine D2-receptor agonist. ent-Naxagolide hydrochloride can be used in the study of extrapyramidal diseases and Parkinson's syndrome.
  • HY-12520AR
    SKF 38393 hydrochloride (Standard)
    Agonist
    SKF 38393 (hydrochloride) (Standard) is the analytical standard of SKF 38393 (hydrochloride). This product is intended for research and analytical applications. SKF 38393 hydrochloride is a selective agonist of the dopamine D1 receptor (D1DR) with an IC50 of 110 nM.
  • HY-14330
    ABT-724
    Agonist
    ABT-724, a chemical probe, is a potent and highly selective dopamine D4 receptor agonist with an EC50 of 12.4 nM for human dopamine D4 receptor. ABT-724 is a potent partial agonist at the rat D4 (EC50 of 14.3 nM) and the ferret D4 receptor (EC50 of 23.2 nM). ABT-724 has no effect on dopamine D1, D2, D3, or D5 receptors. ABT-724 could be useful for the treatment of erectile dysfunction and has favorable side-effect profile.